XNCR (Xencor) Cyclically Adjusted Revenue per Share: $2.92 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XNCR Xencor Inc XNCR
46 GF Score
Price $19.44
GF Value $9.16
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Xencor Cyclically Adjusted Revenue per Share?

Xencor XNCR -0.41% 46 Cyclically Adjusted Revenue per Share is $2.92 as of Mar. 2026. GuruFocus rates XNCR with a GF Score™ of 46/100 and a GF Value™ of $9.16 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Xencor's adjusted revenue per share for the three months ended in Mar. 2026 was $0.060. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.92 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Xencor's average Cyclically Adjusted Revenue Growth Rate was 3.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Xencor was 9.40% per year. The lowest was 9.40% per year. And the median was 9.40% per year.

As of today (2026-07-27), Xencor's current stock price is $19.44. Xencor's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $2.92. Xencor's Cyclically Adjusted PS Ratio of today is 6.66.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xencor was 16.80. The lowest was 2.50. And the median was 7.98.


Xencor  (NAS:XNCR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Xencor's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=19.44/2.92
=6.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xencor was 16.80. The lowest was 2.50. And the median was 7.98.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Xencor Cyclically Adjusted Revenue per Share Related Terms


Xencor Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Xencor's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xencor Cyclically Adjusted Revenue per Share Chart

Xencor Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.20 2.52 2.73 2.88

Xencor Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.81 2.89 2.93 2.88 2.92

XNCR vs VIR, AVBP, SEPN: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Xencor's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xencor Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xencor's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xencor's Cyclically Adjusted PS Ratio falls into.


XNCR
46GF Score
Xencor Inc XNCR
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xencor Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xencor's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.06/330.2130*330.2130
=0.060

Current CPI (Mar. 2026) = 330.2130.

Xencor Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.581 241.018 2.166
201609 0.191 241.428 0.261
201612 0.635 241.432 0.869
201703 0.075 243.801 0.102
201706 0.267 244.955 0.360
201709 0.000 246.819 0.000
201712 0.642 246.524 0.860
201803 0.000 249.554 0.000
201806 0.000 251.989 0.000
201809 0.498 252.439 0.651
201812 0.206 251.233 0.271
201903 1.930 254.202 2.507
201906 0.345 256.143 0.445
201909 0.384 256.759 0.494
201912 0.060 256.974 0.077
202003 0.569 258.115 0.728
202006 0.229 257.797 0.293
202009 0.618 260.280 0.784
202012 0.727 260.474 0.922
202103 0.586 264.877 0.731
202106 1.118 271.696 1.359
202109 0.337 274.310 0.406
202112 2.527 278.802 2.993
202203 1.400 287.504 1.608
202206 0.507 296.311 0.565
202209 0.457 296.808 0.508
202212 0.361 296.797 0.402
202303 0.317 301.836 0.347
202306 0.761 305.109 0.824
202309 0.976 307.789 1.047
202312 0.838 306.746 0.902
202403 0.261 312.332 0.276
202406 0.388 314.175 0.408
202409 0.278 315.301 0.291
202412 0.721 315.605 0.754
202503 0.444 319.799 0.458
202506 0.587 322.561 0.601
202509 0.282 324.800 0.287
202512 0.379 324.054 0.386
202603 0.060 330.213 0.060

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $2.92 mean?
Xencor (XNCR) has a Cyclically Adjusted Revenue per Share of $2.92 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xencor and its competitors.
Is Xencor's Cyclically Adjusted Revenue per Share too high?
Xencor's current Cyclically Adjusted Revenue per Share is $2.92. Overall, Xencor has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xencor's Cyclically Adjusted Revenue per Share compare to VIR and AVBP?
Xencor's Cyclically Adjusted Revenue per Share of $2.92 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xencor and its competitors. Xencor's current Cyclically Adjusted Revenue per Share is $2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xencor stock overvalued right now?
Based on GuruFocus' analysis, Xencor (XNCR) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.16, compared to a current price of $19.44 — trading 112.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $2.92. Xencor's overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Xencor (XNCR), the current Cyclically Adjusted Revenue per Share is $2.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xencor (XNCR) Overvalued in 2026?

Based on GuruFocus' analysis, Xencor stock appears to be overvalued. The current stock price of $19.44 is trading 112.2% above its estimated GF Value™ of $9.16. GuruFocus considers Xencor to be Significantly Overvalued.

Key valuation signals for XNCR:

  • Cyclically Adjusted Revenue per Share: $2.92
  • GF Value™: $9.16 vs. price of $19.44 (112.2% above fair value)
  • GF Score™: 46/100 with 8 warning signs

No single metric tells the full story. See the XNCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xencor Business Description

Other Exchanges XE9:Germany
Address 465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
46GF Score

Get the complete analysis for XNCR

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.44
Price
$9.16
GF Value